WO 2015/066640 Al 7 May 2015 (07.05.2015) P O P C T

Total Page:16

File Type:pdf, Size:1020Kb

WO 2015/066640 Al 7 May 2015 (07.05.2015) P O P C T (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2015/066640 Al 7 May 2015 (07.05.2015) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C12N 15/09 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (21) International Application Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, PCT/US2014/063736 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, 3 November 20 14 (03 .11.20 14) KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, (25) Filing Language: English PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, (26) Publication Language: English SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 61/898,928 1 November 2013 (01. 11.2013) US (84) Designated States (unless otherwise indicated, for every 61/898,932 1 November 2013 (01. 11.2013) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, (71) Applicant: THE RESEARCH INSTITUTE AT NA¬ TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TIONWIDE CHILDREN'S HOSPITAL [US/US]; 700 TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, Children's Drive, Columbus, Ohio 53305 (US). DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, (72) Inventors: SMOYER, William E.; 7465 Lambton Park SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, Road, New Albany, Ohio 43054 (US). AGRAWAL, GW, KM, ML, MR, NE, SN, TD, TG). Shipra; 2741 Oakridge Court, Upper Arlington, Ohio 4322 1 (US). RANSOM, Richard F.; 6100 Whitman Published: Road, Reynoldsburg, Ohio 43068 (US). SUNDARARA- — with international search report (Art. 21(3)) JAN, Saraswathi; 8264 Piney Orchard, Blacklick, Ohio 43004 (US). — with sequence listing part of description (Rule 5.2(a)) (74) Agents: BALL, Rebecca L. et al.; Barnes & Thornburg LLP, 11 South Meridian Street, Indianapolis, Indiana 46204 (US). (54) Title: KIT AND METHOD FOR IDENTIFYING INDIVIDUAL RESPONSIVENESS TO STEROID THERAPY OF NEPH ROTIC SYNDROME -log o © FIGURE 1. (57) Abstract: Provided are a kit and a method for identifying a pediatric patient that is resistant to steroid treatment of Nephrotic Syndrome. KIT AND METHOD FOR IDENTIFYING INDIVIDUAL RESPONSIVENESS TO STEROID THERAPY OF NEPHROTIC SYNDROME CROSS-REFERENCE TO RELATED APPLICATIONS This application is an International Application claiming priority under 35 U.S.C. § 119(e) to U.S. Provisional Application Nos. 61/898,928 and 61/898,932, each filed on November 1, 2013, and the contents of which are both incorporated herein by reference. GOVERNMENT LICENSE RIGHTS This invention was made with government support under NIH R01 DK075533, NIH U01 GM092655, and NIH R01 DK095059-01A1 awarded by the National Institute of Diabetes and Digestive and Kidney Diseases. The government has certain rights in the invention. INCORPORATION BY REFERENCE OF MATERIAL SUBMITTED ELECTRONICALLY Incorporated by reference in its entirety is a computer-readable nucleotide/amino acid sequence listing submitted concurrently herewith and identified as follows: One 14 KB ACII (Text) file named "232343_SEQList_ST25" created on October 31, 2014. BACKGROUND Nephrotic Syndrome is among the most common kidney diseases seen in both children and adults. Nephrotic Syndrome (NS) is a condition caused by damage to the kidneys that leads to several symptoms, such as swelling, low blood protein levels, high cholesterol and triglyceride levels, but most notably, the release of excess protein in the urine (i.e., proteinuria). NS is characterized by increased permeability in the capillaries of the glomerulus (i.e., the filtering unit of the kidney) which results in low blood protein levels and high levels of urine proteins, since the proteins freely pass from the blood into the urine. Research over the past few decades has identified the importance of renal podocytes, the filtering cells of kidney, as a site of injury in NS. For example, kidneys affected by NS have small pores in the podocytes that are large enough to permit proteinuria. The high urine protein levels disable the glomulerus from safely filtering blood, and results in symptoms of NS. The primary therapy for NS is steroids, such as oral glucocorticoids (GC), which effectively result in remission for the majority of patients. However, approximately 20% of patients either present with, or develop, steroid resistance later in their course of treatment; these patients are classified as having Steroid Resistant Nephrotic Syndrome (SRNS). NS patients who show efficacy with steroid treatment are often diagnosed as having Steroid Sensitive Nephrotic Syndrome (SSNS). The known anti-inflammatory and immunosuppressive effects of glucocorticoids (GCs) have served as indirect evidence that their mechanism of action in NS involves inhibition of soluble mediators released by T lymphocytes. In particular, several podocyte proteins have been identified as playing crucial roles in the development of NS, and a number of rare mutations in these proteins have been identified as causative of the disease or for development of resistance to GC treatment. However, the majority of NS patients present with unknown underlying disease etiology. Similarly, the molecular basis for clinical resistance to GC therapy remains largely unclear. Interestingly, children with SRNS fail to enter remission after prolonged GC steroid treatment, and are at high risk for steroid-induced side effects as well as progression of disease. Approximately 10-30% of SRNS are due to mutations in genes specifically expressed in the filtering cells of kidney, the podocytes, while the etiology of the other approximate 80% of cases is unknown. Identification and development of diagnostic tools to identify SRNS at the time of initial clinical presentation of NS could prevent unnecessary exposure to the toxic effects of steroids and improve the treatment of patients with Nephrotic Syndrome. To design individualized therapies for NS patients, a better understanding of both the complex responses to glucocorticoids (GCs) and the factors that determine susceptibility of the disease and resistance to GC is necessary. Unbiased genome-wide, transcriptome-wide, and proteome-wide systems biology approaches have been identified as key tools to help understand complex diseases, including various forms of primary glomerulopathies. Transcriptome-wide sequencing of RNA enables the assessment of the protein-coding potential of all genes of interest expressed in a tissue. For example, RNAseq is a suitable screening approach for identifying the molecular basis of diseases with unknown etiology, including acquired forms of NS. Identification of the type of NS (steroid sensitive vs. steroid resistant) is crucial to determine the best treatment regimen for NS patients. In particular, the ability to provide patients genetic tests to identify resistant cases of NS. The present invention is able to provide reliable testing to identify patients who have or will develop steroid resistant NS, and thus enable the avoidance of patient exposure to potentially ineffective or adverse medications (i.e., steroids). Described herein are a kit and a method for identifying a patient that is resistant to steroid treatment of Nephrotic Syndrome (NS). The kit and the method comprise reagents for detecting the expression of one or more genes or gene products to identify, diagnose, and/or treat NS in patients with a lack of responsiveness to steroids, such as glucocorticoids (GCs). Further described are gene biomarkers that can differentiate between a patient having Steroid Resistant Nephrotic Syndrome (SRNS) and a patient having Steroid Sensitive Nephrotic Syndrome (SSNS). Specifically, the present invention describes a kit or a method to identify steroid resistance in a patient with NS, wherein the patient is a pediatric patient. SUMMARY Disclosed herein are a kit and a method for identifying a patient with resistance to steroid therapy of Nephrotic Syndrome. In an exemplary embodiment of the kit and the method, the patient is a pediatric patient. In an embodiment of the kit, the kit comprises instructional materials. In one embodiment, the kit comprises a plurality of binding reagents. In one embodiment of the kit, the kit comprises binding reagents , wherein each of the binding reagents specifically binds to a gene product encoded by a gene selected from the group of genes consisting of: RFFL, INPP1, MCM2, CSNK1G1, SIGLEC10, AGPAT6, DCAF8, FAM193A, RSPRY1, KCTD20, BLOC1S3, TOE1, ACAD10, SULF2, RAB8A, NCRNA00294, ZNF318, CDK4, TMEM219, PRKCSH, SLC9A7, LEOl, STX4, PTPRK, GANAB, C170RF63, ZC3H18, MED 14, TRAPPC5, EXOC7, ACINI, ITGAL, SH2D1B, TRMT6, NACC1, RECQL5, ZC3H12D, PRR5L, UBE2J2, TOPBP1, GALNT2, BTN2A2, GPR108, CHMP4B, ALDOA, TRAPPC1, SPRYD3, MTMR14, S1PR5, FAM134C, ALDOC, TCP1, CLCN3, NDUFS1, LGALS9, SUPT5H, JARID2, FAM40A, KLF2, AKIRIN1, ZNF782, OCIAD1, KPNA1, KIAA1033, UBE2W, LOC220930, NCRNA00081, ATP11B, SLC2A1, PIGB, SEPHS2, FGFR10P2, GLIPR2, ARHGEF2, S100A8, H2AFY, SELL, TRIM22, ZC3HAV1, MY05A, ZNF641, SRSF4, ZBTB34, NCOA4, ANTXR2, DDX3X, CHST11, PRNP, SLC35B4, GM2A,
Recommended publications
  • Cytogenomic SNP Microarray - Fetal ARUP Test Code 2002366 Maternal Contamination Study Fetal Spec Fetal Cells
    Patient Report |FINAL Client: Example Client ABC123 Patient: Patient, Example 123 Test Drive Salt Lake City, UT 84108 DOB 2/13/1987 UNITED STATES Gender: Female Patient Identifiers: 01234567890ABCD, 012345 Physician: Doctor, Example Visit Number (FIN): 01234567890ABCD Collection Date: 00/00/0000 00:00 Cytogenomic SNP Microarray - Fetal ARUP test code 2002366 Maternal Contamination Study Fetal Spec Fetal Cells Single fetal genotype present; no maternal cells present. Fetal and maternal samples were tested using STR markers to rule out maternal cell contamination. This result has been reviewed and approved by Maternal Specimen Yes Cytogenomic SNP Microarray - Fetal Abnormal * (Ref Interval: Normal) Test Performed: Cytogenomic SNP Microarray- Fetal (ARRAY FE) Specimen Type: Direct (uncultured) villi Indication for Testing: Patient with 46,XX,t(4;13)(p16.3;q12) (Quest: EN935475D) ----------------------------------------------------------------- ----- RESULT SUMMARY Abnormal Microarray Result (Male) Unbalanced Translocation Involving Chromosomes 4 and 13 Classification: Pathogenic 4p Terminal Deletion (Wolf-Hirschhorn syndrome) Copy number change: 4p16.3p16.2 loss Size: 5.1 Mb 13q Proximal Region Deletion Copy number change: 13q11q12.12 loss Size: 6.1 Mb ----------------------------------------------------------------- ----- RESULT DESCRIPTION This analysis showed a terminal deletion (1 copy present) involving chromosome 4 within 4p16.3p16.2 and a proximal interstitial deletion (1 copy present) involving chromosome 13 within 13q11q12.12. This
    [Show full text]
  • Identification of the Binding Partners for Hspb2 and Cryab Reveals
    Brigham Young University BYU ScholarsArchive Theses and Dissertations 2013-12-12 Identification of the Binding arP tners for HspB2 and CryAB Reveals Myofibril and Mitochondrial Protein Interactions and Non- Redundant Roles for Small Heat Shock Proteins Kelsey Murphey Langston Brigham Young University - Provo Follow this and additional works at: https://scholarsarchive.byu.edu/etd Part of the Microbiology Commons BYU ScholarsArchive Citation Langston, Kelsey Murphey, "Identification of the Binding Partners for HspB2 and CryAB Reveals Myofibril and Mitochondrial Protein Interactions and Non-Redundant Roles for Small Heat Shock Proteins" (2013). Theses and Dissertations. 3822. https://scholarsarchive.byu.edu/etd/3822 This Thesis is brought to you for free and open access by BYU ScholarsArchive. It has been accepted for inclusion in Theses and Dissertations by an authorized administrator of BYU ScholarsArchive. For more information, please contact [email protected], [email protected]. Identification of the Binding Partners for HspB2 and CryAB Reveals Myofibril and Mitochondrial Protein Interactions and Non-Redundant Roles for Small Heat Shock Proteins Kelsey Langston A thesis submitted to the faculty of Brigham Young University in partial fulfillment of the requirements for the degree of Master of Science Julianne H. Grose, Chair William R. McCleary Brian Poole Department of Microbiology and Molecular Biology Brigham Young University December 2013 Copyright © 2013 Kelsey Langston All Rights Reserved ABSTRACT Identification of the Binding Partners for HspB2 and CryAB Reveals Myofibril and Mitochondrial Protein Interactors and Non-Redundant Roles for Small Heat Shock Proteins Kelsey Langston Department of Microbiology and Molecular Biology, BYU Master of Science Small Heat Shock Proteins (sHSP) are molecular chaperones that play protective roles in cell survival and have been shown to possess chaperone activity.
    [Show full text]
  • Anti-ARL4A Antibody (ARG41291)
    Product datasheet [email protected] ARG41291 Package: 100 μl anti-ARL4A antibody Store at: -20°C Summary Product Description Rabbit Polyclonal antibody recognizes ARL4A Tested Reactivity Hu, Ms, Rat Tested Application ICC/IF, IHC-P Host Rabbit Clonality Polyclonal Isotype IgG Target Name ARL4A Antigen Species Human Immunogen Recombinant fusion protein corresponding to aa. 121-200 of Human ARL4A (NP_001032241.1). Conjugation Un-conjugated Alternate Names ARL4; ADP-ribosylation factor-like protein 4A Application Instructions Application table Application Dilution ICC/IF 1:50 - 1:200 IHC-P 1:50 - 1:200 Application Note * The dilutions indicate recommended starting dilutions and the optimal dilutions or concentrations should be determined by the scientist. Calculated Mw 23 kDa Properties Form Liquid Purification Affinity purified. Buffer PBS (pH 7.3), 0.02% Sodium azide and 50% Glycerol. Preservative 0.02% Sodium azide Stabilizer 50% Glycerol Storage instruction For continuous use, store undiluted antibody at 2-8°C for up to a week. For long-term storage, aliquot and store at -20°C. Storage in frost free freezers is not recommended. Avoid repeated freeze/thaw cycles. Suggest spin the vial prior to opening. The antibody solution should be gently mixed before use. Note For laboratory research only, not for drug, diagnostic or other use. www.arigobio.com 1/2 Bioinformation Gene Symbol ARL4A Gene Full Name ADP-ribosylation factor-like 4A Background ADP-ribosylation factor-like 4A is a member of the ADP-ribosylation factor family of GTP-binding proteins. ARL4A is similar to ARL4C and ARL4D and each has a nuclear localization signal and an unusually high guaninine nucleotide exchange rate.
    [Show full text]
  • Constitutive Activation of RAS/MAPK Pathway Cooperates with Trisomy 21 and Is Therapeutically Exploitable in Down Syndrome B-Cell Leukemia
    Author Manuscript Published OnlineFirst on March 27, 2020; DOI: 10.1158/1078-0432.CCR-19-3519 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. Constitutive activation of RAS/MAPK pathway cooperates with trisomy 21 and is therapeutically exploitable in Down syndrome B-cell Leukemia Anouchka P. Laurent1,2, Aurélie Siret1, Cathy Ignacimouttou1, Kunjal Panchal3, M’Boyba K. Diop4, Silvia Jenny5, Yi-Chien Tsai5, Damien Ross-Weil1, Zakia Aid1, Naïs Prade6, Stéphanie Lagarde6, Damien Plassard7, Gaelle Pierron8, Estelle Daudigeos-Dubus4, Yann Lecluse4, Nathalie Droin1, Beat Bornhauser5, Laurence C. Cheung3,9, John D. Crispino10, Muriel Gaudry1, Olivier A. Bernard1, Elizabeth Macintyre11, Carole Barin Bonnigal12, Rishi S. Kotecha3,9,13, Birgit Geoerger4, Paola Ballerini14, Jean-Pierre Bourquin5, Eric Delabesse6, Thomas Mercher1,15 and Sébastien Malinge1,3 1INSERM U1170, Gustave Roussy Institute, Université Paris Saclay, Villejuif, France 2Université Paris Diderot, Paris, France 3Telethon Kids Cancer Centre, Telethon Kids Institute, University of Western Australia, Perth, Australia 4Gustave Roussy Institute Cancer Campus, Department of Pediatric and Adolescent Oncology, INSERM U1015, Equipe Labellisée Ligue Nationale contre le Cancer, Université Paris-Saclay, Villejuif, France 5Department of Pediatric Oncology, Children’s Research Centre, University Children’s Hospital Zurich, Zurich, Switzerland 6Centre of Research on Cancer of Toulouse (CRCT), CHU Toulouse, Université Toulouse III, Toulouse, France 7IGBMC, Plateforme GenomEast, UMR7104 CNRS, Ilkirch, France 8Service de Génétique, Institut Curie, Paris, France 9School of Pharmacy and Biomedical Sciences, Curtin University, Bentley, Australia 10Division of Hematology/Oncology, Northwestern University, Chicago, USA 11Hematology, Université de Paris, Institut Necker-Enfants Malades and Assistance Publique – Hopitaux de Paris, Paris, France 12Centre Hospitalier Universitaire de Tours, Tours, France 1 Downloaded from clincancerres.aacrjournals.org on September 30, 2021.
    [Show full text]
  • ZNF226 Is Over-Expressed in Brain Metastatic Breast Cancer-PDF 111920
    1 ZNF226 is over-expressed in brain metastatic breast cancer. 2 Shahan Mamoor East Islip, NY USA1 3 [email protected] 4 5 Metastasis to the brain is a clinical problem in patients with breast cancer1-3. We mined published 6 microarray data4,5 to compare primary and metastatic tumor transcriptomes to discover genes associated with brain metastasis in patients with metastatic breast cancer. We found that the zinc finger protein 226, 7 encoded by ZNF226 was among the genes whose expression was most different in the brain metastases of patients with brain metastatic breast cancer as compared to primary tumors of the breast. ZNF226 may be 8 relevant to processes underlying metastasis of primary tumor-derived cancer cells to the brain in humans 9 with metastatic breast cancer. 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 Keywords: breast cancer, brain metastases, central nervous system metastases, ZNF226, systems biology 26 of breast cancer, targeted therapeutics in breast cancer. 27 28 PAGE 1 1 One report described a 34% incidence of central nervous system metastases in trastuzumab- treated patients with breast cancer2. This alarmingly high frequency of CNS metastasis events demands 2 an enhanced understanding of the transcriptional makeup of brain metastatic tissues to support identification of therapeutic targets, whether they are treatment related or not. We performed a global 3 comparative analysis of primary and metastatic tumors in patients with brain metastatic breast cancer4,5. 4 We discovered significant differential and increased expression of ZNF226 in brain metastatic tissues of patients with metastatic breast cancer.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Primate Specific Retrotransposons, Svas, in the Evolution of Networks That Alter Brain Function
    Title: Primate specific retrotransposons, SVAs, in the evolution of networks that alter brain function. Olga Vasieva1*, Sultan Cetiner1, Abigail Savage2, Gerald G. Schumann3, Vivien J Bubb2, John P Quinn2*, 1 Institute of Integrative Biology, University of Liverpool, Liverpool, L69 7ZB, U.K 2 Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, The University of Liverpool, Liverpool L69 3BX, UK 3 Division of Medical Biotechnology, Paul-Ehrlich-Institut, Langen, D-63225 Germany *. Corresponding author Olga Vasieva: Institute of Integrative Biology, Department of Comparative genomics, University of Liverpool, Liverpool, L69 7ZB, [email protected] ; Tel: (+44) 151 795 4456; FAX:(+44) 151 795 4406 John Quinn: Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, The University of Liverpool, Liverpool L69 3BX, UK, [email protected]; Tel: (+44) 151 794 5498. Key words: SVA, trans-mobilisation, behaviour, brain, evolution, psychiatric disorders 1 Abstract The hominid-specific non-LTR retrotransposon termed SINE–VNTR–Alu (SVA) is the youngest of the transposable elements in the human genome. The propagation of the most ancient SVA type A took place about 13.5 Myrs ago, and the youngest SVA types appeared in the human genome after the chimpanzee divergence. Functional enrichment analysis of genes associated with SVA insertions demonstrated their strong link to multiple ontological categories attributed to brain function and the disorders. SVA types that expanded their presence in the human genome at different stages of hominoid life history were also associated with progressively evolving behavioural features that indicated a potential impact of SVA propagation on a cognitive ability of a modern human.
    [Show full text]
  • Download The
    PROBING THE INTERACTION OF ASPERGILLUS FUMIGATUS CONIDIA AND HUMAN AIRWAY EPITHELIAL CELLS BY TRANSCRIPTIONAL PROFILING IN BOTH SPECIES by POL GOMEZ B.Sc., The University of British Columbia, 2002 A THESIS SUBMITTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF MASTER OF SCIENCE in THE FACULTY OF GRADUATE STUDIES (Experimental Medicine) THE UNIVERSITY OF BRITISH COLUMBIA (Vancouver) January 2010 © Pol Gomez, 2010 ABSTRACT The cells of the airway epithelium play critical roles in host defense to inhaled irritants, and in asthma pathogenesis. These cells are constantly exposed to environmental factors, including the conidia of the ubiquitous mould Aspergillus fumigatus, which are small enough to reach the alveoli. A. fumigatus is associated with a spectrum of diseases ranging from asthma and allergic bronchopulmonary aspergillosis to aspergilloma and invasive aspergillosis. Airway epithelial cells have been shown to internalize A. fumigatus conidia in vitro, but the implications of this process for pathogenesis remain unclear. We have developed a cell culture model for this interaction using the human bronchial epithelium cell line 16HBE and a transgenic A. fumigatus strain expressing green fluorescent protein (GFP). Immunofluorescent staining and nystatin protection assays indicated that cells internalized upwards of 50% of bound conidia. Using fluorescence-activated cell sorting (FACS), cells directly interacting with conidia and cells not associated with any conidia were sorted into separate samples, with an overall accuracy of 75%. Genome-wide transcriptional profiling using microarrays revealed significant responses of 16HBE cells and conidia to each other. Significant changes in gene expression were identified between cells and conidia incubated alone versus together, as well as between GFP positive and negative sorted cells.
    [Show full text]
  • Expression of Genes Encoding Acetyl-Coa Carboxylase, Biotin Synthase, and Acetyl-Coa Generating Enzymes in Arabidopsis Thaliana Jinshan Ke Iowa State University
    Iowa State University Capstones, Theses and Retrospective Theses and Dissertations Dissertations 1997 Expression of genes encoding acetyl-CoA carboxylase, biotin synthase, and acetyl-CoA generating enzymes in Arabidopsis thaliana Jinshan Ke Iowa State University Follow this and additional works at: https://lib.dr.iastate.edu/rtd Part of the Botany Commons, and the Molecular Biology Commons Recommended Citation Ke, Jinshan, "Expression of genes encoding acetyl-CoA carboxylase, biotin synthase, and acetyl-CoA generating enzymes in Arabidopsis thaliana " (1997). Retrospective Theses and Dissertations. 11996. https://lib.dr.iastate.edu/rtd/11996 This Dissertation is brought to you for free and open access by the Iowa State University Capstones, Theses and Dissertations at Iowa State University Digital Repository. It has been accepted for inclusion in Retrospective Theses and Dissertations by an authorized administrator of Iowa State University Digital Repository. For more information, please contact [email protected]. INFORMATION TO USERS This manuscript has been reproduced from the microfilm master. UMI films the text directly fi"om the original or copy submitted. Thus, some thesis and dissertation copies are in typewriter fece, while others may be from any type of computer printer. The quality of this reproduction is dependent upon the quality of the copy submitted. Broken or indistinct print, colored or poor quality illustrations and photographs, print bleedthrough, substandard margins, and improper alignment can adversely aflfect reproduction. In the unlikely event that the author did not send UMI a complete manuscript and there are missing pages, these will be noted. Also, if unauthorized copyright material had to be removed, a note will indicate the deletion.
    [Show full text]
  • Methods in and Applications of the Sequencing of Short Non-Coding Rnas" (2013)
    University of Pennsylvania ScholarlyCommons Publicly Accessible Penn Dissertations 2013 Methods in and Applications of the Sequencing of Short Non- Coding RNAs Paul Ryvkin University of Pennsylvania, [email protected] Follow this and additional works at: https://repository.upenn.edu/edissertations Part of the Bioinformatics Commons, Genetics Commons, and the Molecular Biology Commons Recommended Citation Ryvkin, Paul, "Methods in and Applications of the Sequencing of Short Non-Coding RNAs" (2013). Publicly Accessible Penn Dissertations. 922. https://repository.upenn.edu/edissertations/922 This paper is posted at ScholarlyCommons. https://repository.upenn.edu/edissertations/922 For more information, please contact [email protected]. Methods in and Applications of the Sequencing of Short Non-Coding RNAs Abstract Short non-coding RNAs are important for all domains of life. With the advent of modern molecular biology their applicability to medicine has become apparent in settings ranging from diagonistic biomarkers to therapeutics and fields angingr from oncology to neurology. In addition, a critical, recent technological development is high-throughput sequencing of nucleic acids. The convergence of modern biotechnology with developments in RNA biology presents opportunities in both basic research and medical settings. Here I present two novel methods for leveraging high-throughput sequencing in the study of short non- coding RNAs, as well as a study in which they are applied to Alzheimer's Disease (AD). The computational methods presented here include High-throughput Annotation of Modified Ribonucleotides (HAMR), which enables researchers to detect post-transcriptional covalent modifications ot RNAs in a high-throughput manner. In addition, I describe Classification of RNAs by Analysis of Length (CoRAL), a computational method that allows researchers to characterize the pathways responsible for short non-coding RNA biogenesis.
    [Show full text]
  • Comparison of Orthologs Across Multiple Species by Various Strategies
    COMPARISON OF ORTHOLOGS ACROSS MULTIPLE SPECIES BY VARIOUS STRATEGIES BY HUI LIU DISSERTATION Submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy in Biophysics and Computational Biology in the Graduate College of the University of Illinois at Urbana-Champaign, 2014 Urbana, Illinois Doctoral Committee: Professor Eric Jakobsson, Chair, Director of Research Professor Gene E. Robinson Associate Professor Saurabh Sinha Assistant Professor Jian Ma Abstract Thanks to the improvement of genome sequencing technology, abundant multi-species genomic data now became available and comparative genomics continues to be a fast prospering filed of biological research. Through the comparison of genomes of different organisms, we can understand what, at the molecular level, distinguishes different life forms from each other. It shed light on revealing the evolution of biology. And it also helps to refine the annotations and functions of individual genomes. For example, through comparisons across mammalian genomes, we can give an estimate of the conserved set of genes across mammals and correspondingly, find the species-specific sets of genes or functions. However, comparative genomics can be feasible only if a meaningful classification of genes exists. A natural way to do so is to delineate sets of orthologous genes. However, debates exist about the appropriate way to define orthologs. It is originally defined as genes in different species which derive from speciation events. But such definition is not sufficient to derive orthologous genes due to the complexity of evolutionary events such as gene duplication and gene loss. While it is possible to correctly figure out all the evolutionary events with the true phylogenetic tree, the true phylogenetic tree itself is impractical to be inferred.
    [Show full text]
  • Análise Integrativa De Perfis Transcricionais De Pacientes Com
    UNIVERSIDADE DE SÃO PAULO FACULDADE DE MEDICINA DE RIBEIRÃO PRETO PROGRAMA DE PÓS-GRADUAÇÃO EM GENÉTICA ADRIANE FEIJÓ EVANGELISTA Análise integrativa de perfis transcricionais de pacientes com diabetes mellitus tipo 1, tipo 2 e gestacional, comparando-os com manifestações demográficas, clínicas, laboratoriais, fisiopatológicas e terapêuticas Ribeirão Preto – 2012 ADRIANE FEIJÓ EVANGELISTA Análise integrativa de perfis transcricionais de pacientes com diabetes mellitus tipo 1, tipo 2 e gestacional, comparando-os com manifestações demográficas, clínicas, laboratoriais, fisiopatológicas e terapêuticas Tese apresentada à Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo para obtenção do título de Doutor em Ciências. Área de Concentração: Genética Orientador: Prof. Dr. Eduardo Antonio Donadi Co-orientador: Prof. Dr. Geraldo A. S. Passos Ribeirão Preto – 2012 AUTORIZO A REPRODUÇÃO E DIVULGAÇÃO TOTAL OU PARCIAL DESTE TRABALHO, POR QUALQUER MEIO CONVENCIONAL OU ELETRÔNICO, PARA FINS DE ESTUDO E PESQUISA, DESDE QUE CITADA A FONTE. FICHA CATALOGRÁFICA Evangelista, Adriane Feijó Análise integrativa de perfis transcricionais de pacientes com diabetes mellitus tipo 1, tipo 2 e gestacional, comparando-os com manifestações demográficas, clínicas, laboratoriais, fisiopatológicas e terapêuticas. Ribeirão Preto, 2012 192p. Tese de Doutorado apresentada à Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo. Área de Concentração: Genética. Orientador: Donadi, Eduardo Antonio Co-orientador: Passos, Geraldo A. 1. Expressão gênica – microarrays 2. Análise bioinformática por module maps 3. Diabetes mellitus tipo 1 4. Diabetes mellitus tipo 2 5. Diabetes mellitus gestacional FOLHA DE APROVAÇÃO ADRIANE FEIJÓ EVANGELISTA Análise integrativa de perfis transcricionais de pacientes com diabetes mellitus tipo 1, tipo 2 e gestacional, comparando-os com manifestações demográficas, clínicas, laboratoriais, fisiopatológicas e terapêuticas.
    [Show full text]